PNT

POINT Biopharma Global Inc. (PNT) | Rumor.io

POINT Biopharma Global

PNT

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about PNT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% -0.02	0% +0	0% +0

Sep 4

POINT Biopharma Global Inc. announces a $60 million milestone in its revenue growth.

Generated by AI

Sentiment

Of the messages about PNT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	100% 0
Bearish	—	—	0%	0% 0

Dec 8

$PNT has nearly doubled in price since a specific post, with a potential 783% move to a breakout target at $2.963.
POINT Biopharma Global Inc.'s ($PNT) price has increased by over 130% so far, with a strong demand zone and increasing volume on Binance.
$PNT has reached a take-profit target on Binance, achieving a 17.86% profit in 18 hours and 45 minutes, with some investors already taking profits.

Generated by AI

Topics

Of the messages about PNT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	94.1%	50.76%
Analysts	0%	0%	0%	46.48%
Controversies	0%	0%	0%	0.04%
Earnings	0%	0%	0%	0.15%
Macro	0%	0%	5.9%	2.57%
Technical Analysis	0%	0%	0%	0%

Announcements· Jul 2

POINT Biopharma Global Inc. has developed an anti-GPS jamming PNT ASIC for DCs, IoT, and physical AI.
The company's PNT network has potential uses beyond navigation and search and rescue, including military applications.
Iridium has announced a new chip that could be used as a security backup or failsafe solution in mission-critical GPS receivers.

Technical Analysis· Dec 8

POINT Biopharma Global Inc. ($PNT) has seen a 200% price increase since buyers' funds reappeared at 10.20, with the stock currently at the first resistance region of 0.3383.
The stock has effectively supported in the green support area, and a potential retrace to 0.2659 could occur before continuing the upward trend, with a potential target of 0.5463 and a final target of 0.7935.
Since the wedge breakout, $PNT has delivered a +110% profit, with the stock showing a strong upward trend.

Generated by AI

Community

Of the messages about PNT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	0.33%
Newcomers	100%	100%	100%	99.67%

Regulars· Oct 3

POINT Biopharma Global Inc. ($PNT) is being acquired by Eli Lilly and Company ($LLY) for $12.50 per share in a cash tender offer, valued at approximately $1.4 billion.
The acquisition is expected to provide significant value to $LLY, particularly in its earlier pipeline assets, such as FAP-α and Ac-225, which are critical to commercial success.
The acquisition price is significantly lower than the company's recent trading price, with $PNT trading 7453% above average volume and closing up 84.89% on the news.

Newcomers· Sep 4

PNT is mentioned as a potential investment opportunity with a target price of $60M.
Newcomers are discussing PNT's potential for growth, with some users sharing their hopes for the company's future.
There is a mention of a "transaction proxy" associated with PNT, but the context is unclear.

Generated by AI

Recently published Metastatic Castration-resistant Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, metastatic castration-resistant prostate cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

2mo agoYahoo Finance

Also Discussed

Investors talking about PNT also mention

#	Name	Attention
1	United Natural Foods Inc.UNFI	0%new
2	AKRO - Akero Therapeutics, Inc.	——
3	Medtronic plcMDT	0%+0
4	Fidelity National Information Services, Inc.FIS	0%new
5	ArdorARDR	0%0
6	Organon & Co.OGN	0%0
7	Brookfield Wealth Solutions Ltd.BNT	0%new
8	OntologyONT	0%0
9	FLM - First Trust Alerian U.S. NextGen Infrastructure ETF	——
10	Lantheus Holdings Inc.LNTH	0%0